Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
2.
Acta méd. colomb ; 17(3): 180-5, mayo-jun. 1992. tab
Article in Spanish | LILACS | ID: lil-183236

ABSTRACT

The etiologic agent of this severe form of hepatitis was identified by Rizzetto et al in Italy in 1977. The Delta virus resembles satellite viruses of plants which can not replicate without another specific virus. In this particular case hepatitis B virus is the helper agent. Clinically this form of hepatitis is characterized by two presentations: coinfeccion, which means simultaneous infection of a host with hepatitis B virus and hepatitis D virus. This variety of hepatitis can present with two distinct peaks of transaminases and usually resolves completely in most of the cases, however 0-4 percent can evolve to chronic hepatitis and 25 percent of the cases of fulminant hepatitis are due to this viral association. The diagnosis can be established demonstrating anti-HDV IgM or HDV-RNA or HDV antigen in the serum. In essence coinfection makers acute hepatic failure more common and the mortality is significantly higher than hepatitis B infections by itself. The second type of clinical presentation is superinfection, which means infection with the Delta virus of a patient previously infected with the hepatitis B virus (healthy carrier). Initially the patient develop a typical acute viral hepatitis in 50-70 percent of the cases, and 30-50 percent can have asymptomatic infection. The real problem with this presentation is that 20-90 percent of the cases evolved to chronicity: chronic active hepatitis and cirrhosis. The diagnosis can be made demonstrating anti-HDB IgM and anti-HDV IfG, although this last one is usually transitory. A liver biopsy can show HDV RNA or HDV antigen using special immunostainings...


Subject(s)
Humans , Hepatitis Delta Virus/growth & development , Hepatitis Delta Virus/immunology , Hepatitis Delta Virus/isolation & purification , Hepatitis Delta Virus/pathogenicity , Hepatitis Delta Virus/physiology , Hepatitis D/complications , Hepatitis D/diagnosis , Hepatitis D/drug therapy , Hepatitis D/epidemiology , Hepatitis D/etiology , Hepatitis D/immunology , Hepatitis D/physiopathology , Hepatitis D/therapy
SELECTION OF CITATIONS
SEARCH DETAIL